Last edition
News about Global Pharma
Panacea Biotec Secures INR Over 127 Crore Order for Bivalent Oral Polio Vaccine from CMSS
The Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, Government of India, has awarded Panacea Biotec a contract to supply bivalent oral polio vaccine (bOPV) worth INR 127.20 Crore.
Global Pharma | 09/10/2025 | By Dineshwori | 131
Lumen Bioscience Strengthens Leadership Team to Advance Oral Biologics Pipeline
US-based clinical-stage biotech Lumen Bioscience, which develops orally delivered biologics, has announced key leadership enhancements as it advances its portfolio toward commercial launch.
Global Pharma | 09/10/2025 | By Dineshwori | 267
Enzene Integrates Virtuosi to Develop Globally Competitive Pharmaceutical Workforce
With this collaboration, Enzene becomes the first Indian company to partner with Virtuosi —marking a major milestone in building a fully skilled and globally competitive pharmaceutical workforce.
Global Pharma | 09/10/2025 | By Dineshwori | 193
Daiichi Sankyo Files sNDA in Japan for ENHERTU Plus Pertuzumab in HER2-Positive Breast Cancer
Daiichi Sankyo has filed a supplemental NDA in Japan for ENHERTU plus Pertuzumab in HER2-positive breast cancer. If approved, this therapy could enter the first-line metastatic setting and has the potential to become a new standard of care.
<br />
Global Pharma | 08/10/2025 | By Dineshwori | 525
Merck Completes Acquisition of Verona Pharma
The acquisition of Verona Pharma strengthens Merck’s cardio-pulmonary portfolio with addition of Ohtuvayre (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade.
Global Pharma | 08/10/2025 | By Dineshwori | 153
Clearmind Biomedical Signs US Distribution Agreement with Sutter Medical Technologies USA
Clearmind Biomedical has partnered with Sutter Medical to exclusively distribute its 510(k)-cleared Neuroblade Neuro-Endoscope System in the US, advancing treatment for intracerebral hemorrhage—one of the most severe and hard-to-treat stroke types.
Global Pharma | 06/10/2025 | By Dineshwori | 241
Hikma, Celltrion Deepen Ties to Boost Biosimilar Access in Middle East and North Africa
British multinational pharmaceutical company Hikma Pharmaceuticals has signed new exclusive licensing agreements with its long-standing partner, South Korea’s Celltrion, covering the Middle East and North Africa (MENA) region.
Global Pharma | 06/10/2025 | By Dineshwori | 335
Avobis Bio’s lead therapeutic, AVB-114, has received FDA’s RMAT designation for Crohn’s perianal fistulas, building on its Fast Track status to accelerate development with enhanced regulatory support and guidance.
Global Pharma | 06/10/2025 | By Dineshwori | 276
FDA Flags Lupin's Pithampur Manufacturing Facility with Official Action Indicated Status
Lupin stated that it is actively engaging with the U.S. regulator and remains committed to maintaining full compliance with current Good Manufacturing Practice (cGMP) standards across all its manufacturing sites.
Global Pharma | 06/10/2025 | By Darshana | 482
Lupin Launches Liraglutide Injection in US
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen is bioequivalent to Victoza injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc.
Global Pharma | 04/10/2025 | By Dineshwori | 211
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy